CEO Clay Siegall was paid $7,682,601 in fiscal year 2025, ↓ down 16.7% from fiscal year 2024 (SEC filing 0001140361-26-016685 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$7,682,601 ↓ Clay Siegall total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 98.44% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
IMNM's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Clay Siegall | $735,000 | — | $0 | $6,272,810 | $661,500 | $0 | $13,291 | $7,682,601 |
| President, Chief Executive Officer and Chairman of the Board | ||||||||
| Max Rosett | 472,500 | — | 0 | 1,623,090 | 278,800 | 0 | 411,167 | 2,785,557 |
| Chief Financial Officer | ||||||||
| Robert Lechleider | 530,300 | — | 0 | 1,897,525 | 307,600 | 0 | 12,193 | 2,747,618 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Clay Siegall | $7,682,601 | $9,226,774 | $14,866,831 | ↓ −1,544,173 |
| Max Rosett | 2,785,557 | — | — | — |
| Robert Lechleider | 2,747,618 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Immunome's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IMNM reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name IMNM as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Carol Schafer | Independent Director | $195,000 |
| Isaac Barchas, J.D | Lead Independent Director | $210,000 |
| James Boylan | Independent Director | $190,000 |
| Jean-Jacques Bienaim | Independent Director | — |
| Philip Wagenheim | Independent Director | $175,000 |
| Sandra Swain, M.D | Independent Director | $182,500 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jean Jacques Bienaime | Director | 2026-05-15 | A | 5,000 | $21 | $103,500 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | D | 10,000 | 19 | 194,100 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | A | 1,000 | 19 | 19,270 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | A | 3,500 | 19 | 68,110 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | A | 6,000 | 19 | 116,880 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | D | 500 | 19 | 9,720 | Common | Form 4 ↗ |
| Philip Wagenheim | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra M. Swain | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carol Schafer | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Boylan | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-06-15 | D | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-06-15 | D | 60,000 | 18 | 1,093,800 | Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-06-15 | A | 60,000 | 1 | 63,000 | Common | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | D | 55,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | D | 14,420 | 21 | 297,917 | Common, open-market sale | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | D | 40,580 | 20 | 793,745 | Common, open-market sale | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | A | 55,000 | 9 | 480,150 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-06-30 | D | 101,050 | 21 | 2,134,176 | Common, indirect | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 16,072 | 23 | 376,728 | Common, open-market sale | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-02 | D | 75,665 | 22 | 1,691,113 | Common, indirect | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | A | 55,000 | 9 | 480,150 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-02 | D | 24,335 | 23 | 567,736 | Common, indirect | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 55,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 16,214 | 23 | 369,031 | Common, open-market sale | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 22,714 | 22 | 498,572 | Common, open-market sale | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-06 | D | 83,094 | 24 | 2,003,396 | Common, indirect | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-07 | — | 1,092 | — | — | 1 insider, 1 accrual row | ||
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-07 | D | 1,092 | 25 | 27,300 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-07 | D | 16,906 | 24 | 409,125 | Common, indirect | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-07 | A | 1,092 | 13 | 14,109 | Common | Form 4 ↗ |
| Clay Siegall | Director | 2026-07-23 | A | 360,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Clay Siegall | Director | 2026-07-23 | A | 180,000 | 0 | 0 | RSU | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-23 | A | 108,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 2026-07-23 | A | 76,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 2026-07-23 | A | 38,250 | 0 | 0 | RSU | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-23 | A | 62,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-23 | A | 31,250 | 0 | 0 | RSU | Form 4 ↗ |
| Philip Tsai | Chief Technical Officer | 2026-07-23 | A | 38,250 | 0 | 0 | RSU | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-23 | A | 54,000 | 0 | 0 | RSU | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-07-23 | A | 94,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-07-23 | A | 47,250 | 0 | 0 | RSU | Form 4 ↗ |
| Philip Tsai | Chief Technical Officer | 2026-07-23 | A | 76,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-07-23 | A | 76,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-07-23 | A | 38,250 | 0 | 0 | RSU | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | D | 90,616 | 25 | 2,273,555 | Common, open-market sale | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | A | 40,250 | 11 | 426,650 | Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | D | 50,366 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | D | 40,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | A | 50,366 | 13 | 650,729 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-06 | D | 20,840 | 26 | 543,090 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-07 | D | 15,248 | 26 | 397,363 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-10 | D | 10,125 | 26 | 263,959 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-11 | D | 62,291 | 26 | 1,633,893 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-12 | D | 11,048 | 27 | 301,058 | Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | A | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | D | 8,800 | 0 | 0 | Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | D | 13,200 | 25 | 334,224 | Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | A | 18,000 | 1 | 24,300 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jean Jacques Bienaime | Director | 2026-05-15 | A | 5,000 | $21 | $103,500 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | D | 10,000 | 19 | 194,100 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | A | 1,000 | 19 | 19,270 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | A | 3,500 | 19 | 68,110 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | A | 6,000 | 19 | 116,880 | Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-05 | D | 500 | 19 | 9,720 | Common | Form 4 ↗ |
| Philip Wagenheim | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra M. Swain | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carol Schafer | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Boylan | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jean Jacques Bienaime | Director | 2026-06-10 | A | 9,897 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-06-15 | D | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-06-15 | D | 60,000 | 18 | 1,093,800 | Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-06-15 | A | 60,000 | 1 | 63,000 | Common | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | D | 55,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | D | 14,420 | 21 | 297,917 | Common, open-market sale | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | D | 40,580 | 20 | 793,745 | Common, open-market sale | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-06-25 | A | 55,000 | 9 | 480,150 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-06-30 | D | 101,050 | 21 | 2,134,176 | Common, indirect | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 16,072 | 23 | 376,728 | Common, open-market sale | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-02 | D | 75,665 | 22 | 1,691,113 | Common, indirect | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | A | 55,000 | 9 | 480,150 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-02 | D | 24,335 | 23 | 567,736 | Common, indirect | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 55,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 16,214 | 23 | 369,031 | Common, open-market sale | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-02 | D | 22,714 | 22 | 498,572 | Common, open-market sale | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-06 | D | 83,094 | 24 | 2,003,396 | Common, indirect | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-07 | D | 1,092 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-07 | D | 1,092 | 25 | 27,300 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-07-07 | D | 16,906 | 24 | 409,125 | Common, indirect | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-07 | A | 1,092 | 13 | 14,109 | Common | Form 4 ↗ |
| Clay Siegall | Director | 2026-07-23 | A | 360,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Clay Siegall | Director | 2026-07-23 | A | 180,000 | 0 | 0 | RSU | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-23 | A | 108,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 2026-07-23 | A | 76,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra G. Stoneman | CHIEF LEGAL OFFICER & GC | 2026-07-23 | A | 38,250 | 0 | 0 | RSU | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-23 | A | 62,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-07-23 | A | 31,250 | 0 | 0 | RSU | Form 4 ↗ |
| Philip Tsai | Chief Technical Officer | 2026-07-23 | A | 38,250 | 0 | 0 | RSU | Form 4 ↗ |
| Robert Lechleider | Chief Medical Officer | 2026-07-23 | A | 54,000 | 0 | 0 | RSU | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-07-23 | A | 94,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Max Rosett | Chief Financial Officer | 2026-07-23 | A | 47,250 | 0 | 0 | RSU | Form 4 ↗ |
| Philip Tsai | Chief Technical Officer | 2026-07-23 | A | 76,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-07-23 | A | 76,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-07-23 | A | 38,250 | 0 | 0 | RSU | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | D | 90,616 | 25 | 2,273,555 | Common, open-market sale | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | A | 40,250 | 11 | 426,650 | Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | D | 50,366 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | D | 40,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kinney Horn | CHIEF BUSINESS OFFICER | 2026-08-04 | A | 50,366 | 13 | 650,729 | Common | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-06 | D | 20,840 | 26 | 543,090 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-07 | D | 15,248 | 26 | 397,363 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-10 | D | 10,125 | 26 | 263,959 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-11 | D | 62,291 | 26 | 1,633,893 | Common, indirect | Form 4 ↗ |
| Isaac Barchas | Director | 2026-08-12 | D | 11,048 | 27 | 301,058 | Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | A | 18,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | D | 8,800 | 0 | 0 | Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | D | 13,200 | 25 | 334,224 | Common | Form 4 ↗ |
| Jack Higgins | Chief Scientific Officer | 2026-09-11 | A | 18,000 | 1 | 24,300 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Max Rosett | OPTION | — | — | — | — | — | $1,623,090 |
| Clay Siegall | OPTION | — | — | — | — | — | 6,272,810 |
| Robert Lechleider | OPTION | — | — | — | — | — | 1,897,525 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Max Rosett | $0 | $0 | $1,623,090 | 0.0% |
| Clay Siegall | 0 | 0 | 6,272,810 | 0.0% |
| Robert Lechleider | 0 | 0 | 1,897,525 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Lechleider | Option | 242,000 | 10.6 | — |
| Max Rosett | Option | 18,125 | 14.4 | — |
| Clay Siegall | Option | 533,334 | 12.92 | — |
| Max Rosett | Option | 91,146 | 16.57 | — |
| Max Rosett | Option | 8,366 | 1.05 | — |
| Robert Lechleider | Option | 133,334 | 12.92 | — |
| Max Rosett | Option | 126,667 | 12.92 | — |
| Clay Siegall | Option | 800,000 | 10.6 | — |
| Clay Siegall | Option | 979,495 | 5.91 | — |
| Max Rosett | Option | 207,000 | 10.6 | — |
| Robert Lechleider | Option | 183,334 | 8.73 | — |
Our executive compensation program is designed to align pay with Company performance and long-term stockholder value creation.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 90,908,436 | 1,442,116 | 31,014 | 98.44% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-09 | 98.44%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Isaac Barchas, J.DIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance (Chair) | $75,000 | $0 | $135,000 | $0 | $0 | $210,000 |
| Carol SchaferIndependent · Audit (Chair) · Nominating and Corporate Governance | 60,000 | 0 | 135,000 | 0 | 0 | 195,000 |
| James BoylanIndependent · Compensation (Chair) · Nominating and Corporate Governance | 55,000 | 0 | 135,000 | 0 | 0 | 190,000 |
| Jean-Jacques BienaiméIndependent · Audit · Compensation | 52,500 | 0 | 135,000 | 0 | 0 | 187,500 |
| Sandra Swain, M.DIndependent · Audit | 47,500 | 0 | 135,000 | 0 | 0 | 182,500 |
| Philip WagenheimIndependent · Compensation | 40,000 | 0 | 135,000 | 0 | 0 | 175,000 |
| Clay Siegall, Ph.DEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $135,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $330,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $330,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunome | 2025 | Clay Siegall | $735,000 | $0 | $6,272,810 | $661,500 | $7,682,601 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Clay Siegall | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493 |
| 2 | Section 01, Max Rosett | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 2,785,557. Filing ↗machine: r4 · c21 · span 424106–424115 |
| 3 | Section 01, Robert Lechleider | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 2,747,618. Filing ↗machine: r5 · c21 · span 428410–428419 |
| 4 | Section 03, Max Rosett OPTION | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r4 · c12 · span 422704–422713 |
| 5 | Section 03, Clay Siegall OPTION | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r2 · c12 · span 414755–414764 |
| 6 | Section 03, Robert Lechleider OPTION | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r5 · c12 · span 426795–426804 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-03 | 0001193125-26-088172 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Isaac Barchas, J.D | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 210,000. Filing ↗machine: t97 · r2 · c9 · span 658329–658508 |
| 9 | Section 08, Carol Schafer | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 195,000. Filing ↗machine: t97 · r3 · c9 · span 660052–660231 |
| 10 | Section 08, James Boylan | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 190,000. Filing ↗machine: t97 · r5 · c9 · span 663792–663971 |
| 11 | Section 08, Jean-Jacques Bienaimé | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 187,500. Filing ↗ |
| 12 | Section 08, Sandra Swain, M.D | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 182,500. Filing ↗machine: t97 · r6 · c9 · span 665790–665969 |
| 13 | Section 08, Philip Wagenheim | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 175,000. Filing ↗machine: t97 · r7 · c9 · span 667419–667597 |
| 14 | Section 08, Clay Siegall, Ph.D | DEF 14A | 2026-04-24 | 0001140361-26-016685 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 02, Jean Jacques Bienaime 2026-05-15 | Form 4 | 2026-05-19 | 0001221590-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Jean Jacques Bienaime 2026-06-05 | Form 4 | 2026-06-09 | 0001221590-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Jean Jacques Bienaime 2026-06-05 | Form 4 | 2026-06-09 | 0001221590-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Jean Jacques Bienaime 2026-06-05 | Form 4 | 2026-06-09 | 0001221590-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Jean Jacques Bienaime 2026-06-05 | Form 4 | 2026-06-09 | 0001221590-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Jean Jacques Bienaime 2026-06-05 | Form 4 | 2026-06-09 | 0001221590-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Philip Wagenheim 2026-06-10 | Form 4 | 2026-06-12 | 0001405684-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Sandra M. Swain 2026-06-10 | Form 4 | 2026-06-12 | 0001908755-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Carol Schafer 2026-06-10 | Form 4 | 2026-06-12 | 0001272181-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Isaac Barchas 2026-06-10 | Form 4 | 2026-06-12 | 0001808343-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, James Boylan 2026-06-10 | Form 4 | 2026-06-12 | 0001953094-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Jean Jacques Bienaime 2026-06-10 | Form 4 | 2026-06-12 | 0001221590-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Max Rosett 2026-06-15 | Form 4 | 2026-06-17 | 0001994071-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Max Rosett 2026-06-15 | Form 4 | 2026-06-17 | 0001994071-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Max Rosett 2026-06-15 | Form 4 | 2026-06-17 | 0001994071-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Robert Lechleider 2026-06-25 | Form 4 | 2026-06-29 | 0001997584-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Robert Lechleider 2026-06-25 | Form 4 | 2026-06-29 | 0001997584-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Robert Lechleider 2026-06-25 | Form 4 | 2026-06-29 | 0001997584-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Robert Lechleider 2026-06-25 | Form 4 | 2026-06-29 | 0001997584-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Isaac Barchas 2026-06-30 | Form 4 | 2026-07-02 | 0001808343-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Robert Lechleider 2026-07-02 | Form 4 | 2026-07-07 | 0001997584-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Isaac Barchas 2026-07-02 | Form 4 | 2026-07-02 | 0001808343-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Robert Lechleider 2026-07-02 | Form 4 | 2026-07-07 | 0001997584-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Isaac Barchas 2026-07-02 | Form 4 | 2026-07-02 | 0001808343-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Robert Lechleider 2026-07-02 | Form 4 | 2026-07-07 | 0001997584-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Robert Lechleider 2026-07-02 | Form 4 | 2026-07-07 | 0001997584-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Robert Lechleider 2026-07-02 | Form 4 | 2026-07-07 | 0001997584-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Isaac Barchas 2026-07-06 | Form 4 | 2026-07-07 | 0001808343-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Kinney Horn 2026-07-07 | Form 4 | 2026-07-09 | 0001831215-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Kinney Horn 2026-07-07 | Form 4 | 2026-07-09 | 0001831215-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Isaac Barchas 2026-07-07 | Form 4 | 2026-07-07 | 0001808343-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Kinney Horn 2026-07-07 | Form 4 | 2026-07-09 | 0001831215-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Clay Siegall 2026-07-23 | Form 4 | 2026-07-27 | 0001167496-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Clay Siegall 2026-07-23 | Form 4 | 2026-07-27 | 0001167496-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Robert Lechleider 2026-07-23 | Form 4 | 2026-07-27 | 0001997584-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Sandra G. Stoneman 2026-07-23 | Form 4 | 2026-07-27 | 0001831144-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Sandra G. Stoneman 2026-07-23 | Form 4 | 2026-07-27 | 0001831144-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Kinney Horn 2026-07-23 | Form 4 | 2026-07-27 | 0001831215-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Kinney Horn 2026-07-23 | Form 4 | 2026-07-27 | 0001831215-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Philip Tsai 2026-07-23 | Form 4 | 2026-07-27 | 0002026600-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Robert Lechleider 2026-07-23 | Form 4 | 2026-07-27 | 0001997584-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Max Rosett 2026-07-23 | Form 4 | 2026-07-27 | 0001994071-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Max Rosett 2026-07-23 | Form 4 | 2026-07-27 | 0001994071-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Philip Tsai 2026-07-23 | Form 4 | 2026-07-27 | 0002026600-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Jack Higgins 2026-07-23 | Form 4 | 2026-07-27 | 0001993684-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Jack Higgins 2026-07-23 | Form 4 | 2026-07-27 | 0001993684-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Kinney Horn 2026-08-04 | Form 4 | 2026-08-06 | 0001831215-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Kinney Horn 2026-08-04 | Form 4 | 2026-08-06 | 0001831215-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Kinney Horn 2026-08-04 | Form 4 | 2026-08-06 | 0001831215-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Kinney Horn 2026-08-04 | Form 4 | 2026-08-06 | 0001831215-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Kinney Horn 2026-08-04 | Form 4 | 2026-08-06 | 0001831215-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Isaac Barchas 2026-08-06 | Form 4 | 2026-08-10 | 0001808343-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Isaac Barchas 2026-08-07 | Form 4 | 2026-08-10 | 0001808343-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Isaac Barchas 2026-08-10 | Form 4 | 2026-08-12 | 0001808343-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Isaac Barchas 2026-08-11 | Form 4 | 2026-08-12 | 0001808343-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Isaac Barchas 2026-08-12 | Form 4 | 2026-08-12 | 0001808343-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Jack Higgins 2026-09-11 | Form 4 | 2026-09-15 | 0001993684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Jack Higgins 2026-09-11 | Form 4 | 2026-09-15 | 0001993684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Jack Higgins 2026-09-11 | Form 4 | 2026-09-15 | 0001993684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Jack Higgins 2026-09-11 | Form 4 | 2026-09-15 | 0001993684-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 06, 2026 vote | Form 8-K | 2026-06-12 | 0001193125-26-269383 | Item 5.07 · say-on-pay result. As reported: 98.44% (votes for as printed: 90,908,436). Filing ↗ |
| 76 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 77 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 78 | Section 09b board cost (computed) | Computed | — | — | Cash 330,000 + equity 0 + all other 0 = 330,000, summed across the director compensation table rows.machine: formula: Σ = 330,000 |
| 79 | Immunome (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016685 | CEO total compensation as printed in Immunome's own proxy. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.